ストックスクリーナーアプリを入手
545.53
0.55%
3.01
アフターアワーズ：
545.53
Regeneron Pharmaceuticals Inc (REGN) 最新ニュース
Evergreen Wealth Management LLC Invests $3.59 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Neutralizing Antibody Market Surges with Monoclonal Therapy & - openPR.com
South Dakota Investment Council Buys New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Private Advisor Group LLC Purchases 1,957 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
What analysts say about Regeneron Pharmaceuticals Inc. stockSuperior trading gains - PrintWeekIndia
Regeneron Pharmaceuticals Inc. Stock Analysis and ForecastDynamic investment growth - PrintWeekIndia
Is Regeneron Pharmaceuticals Inc. a good long term investmentHigh-yield growth strategies - jammulinksnews.com
Morse Asset Management Inc Has $2.61 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
What drives Regeneron Pharmaceuticals Inc. stock priceMarket-crushing profits - Autocar Professional
678 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by AustralianSuper Pty Ltd - MarketBeat
Massachusetts Financial Services Co. MA Has $13.30 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Apollon Wealth Management LLC Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals Stock: Is Wall Street Bullish or Bearish? - MSN
Edgestream Partners L.P. Cuts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Balentine LLC Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Victory Capital Management Inc. Sells 42,722 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Sumitomo Life Insurance Co. - MarketBeat
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead. - The Motley Fool
Cwm LLC Increases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron’s New Study on Anticoagulant Alternatives: A Potential Game Changer? - TipRanks
Regeneron’s Promising Phase 3 Trial for Follicular Lymphoma: A Potential Game-Changer? - TipRanks
Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold? - The Globe and Mail
Bailard Inc. Trims Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Does Regeneron Pharmaceuticals (NASDAQ:REGN) Have A Healthy Balance Sheet? - 富途牛牛
Wealthfront Advisers LLC Sells 1,173 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Las bolsas europeas suben, con el foco en los resultados - Yahoo Finanzas
47,567 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by OVERSEA CHINESE BANKING Corp Ltd - MarketBeat
Cutter & CO Brokerage Inc. Raises Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game-Changer for Chronic Rhinosinusitis - TipRanks
Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Market Game-Changer? - TipRanks
Regeneron’s Promising Obesity Treatment Study: A Potential Game-Changer? - TipRanks
Red Biotechnology Market Attracts Investments from Major - openPR.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Holdings Boosted by Concord Wealth Partners - MarketBeat
Cullen Frost Bankers Inc. Has $4.36 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Asahi Life Asset Management CO. LTD. Makes New $434,000 Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Arizona State Retirement System - MarketBeat
UBS Raises Regeneron (REGN) Price Target, Maintains Neutral Rating - MSN
Regeneron’s Innovative Approach in Follicular Lymphoma Treatment: A New Phase 3 Trial - TipRanks
Retinal Vein Occlusion Market Trends: Surge in Anti-VEGF - openPR.com
Grandfield & Dodd LLC Acquires 611 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Unexpected Trends Reshaping the Diabetic Retinopathy Market - openPR.com
Regeneron and Intellia’s Gene Therapy Study: A Potential Game-Changer for Hemophilia B - TipRanks
CenterBook Partners LP Sells 10,270 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Concord Asset Management LLC VA Has $1.33 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
0.00%
0.27%
大文字化:
|
ボリューム (24 時間):